Mồi IL15-179-R
75 Mồi IL15-647-F
76 Mồi icasp9-R
78 5x10 6 10 7 2x10 7 3x10 7 0 20 40 60 80 100 Lượng tế bào % tế b ào C D 3 + biểu h iện C A R
Hình S1. Tỷ lệ tế bào sống CD3+ biểu hiện CAR sau 24 giờ chuyển nạp với các lượng PBMC khác nhau
Hình S2. Kết quả phân tích đếm dịng chảy tế bào CD3+ biểu hiện CAR trên các dịng tế bào CAR-T thế hệ thứ hai và thế hệ thứ tư
79
TÀI LIỆU THAM KHẢO
1. A. Jemal, R. Siegel, J. Xu, and E. Ward, "Cancer statistics, 2010," (in eng), CA Cancer J Clin, vol. 60, no. 5, pp. 277-300, Sep-Oct 2010. 2. T. Terwilliger and M. Abdul-Hay, "Acute lymphoblastic leukemia: a
comprehensive review and 2017 update," (in eng), Blood Cancer J, vol. 7, no. 6, p. e577, Jun 30 2017.
3. M. Stanulla and M. Schrappe, "Treatment of childhood acute
lymphoblastic leukemia," (in eng), Semin Hematol, vol. 46, no. 1, pp. 52- 63, Jan 2009.
4. N. Howlader, et al., "SEER Cancer Statistics Review, 1975-2014,"
National Cancer Institute, Bethesda, MD., 2017.
5. American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). . Available: https://www.cancer.org/cancer/acute-myeloid- leukemia/about/key-statistics.html.
6. Available: http://www.sannhinghean.vn/tin-tuc-8/benh-bach-cau-cap-o- tre-em-517
7. P. C. Dũng, "Điều trị bệnh bạch cầu cấp dòng lympho người lớn bằng phác đồ LALA94," Luận văn Tốt nghiệp bác sĩ Chuyên khoa II, Đại học Y Dược TP.HCM, 2006.
8. Đ. V. Chính, "Xu hướng biến đổi của mơ hình bệnh lý huyết học và một số đáp ứng về nguồn lực tại Viện Huyết học - Truyền máu TW Giai đoạn 2010-2014," Trường Đại học Y tế cơng cộng, Hà Nội, 2016.
9. B. Bielorai et al., "Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant," (in eng), Pediatr Hematol Oncol, vol. 30, no. 6, pp. 574-82, Sep 2013.
10. J. M. Chessells et al., "Down's syndrome and acute lymphoblastic
leukaemia: clinical features and response to treatment," (in eng), Archives of disease in childhood, vol. 85, no. 4, pp. 321-325, 2001.
11. J. German, "Bloom's syndrome. XX. The first 100 cancers," (in eng),
Cancer Genet Cytogenet, vol. 93, no. 1, pp. 100-6, Jan 1997.
12. A. Shah, B. M. John, and V. Sondhi, "Acute lymphoblastic leukemia with treatment--naive Fanconi anemia," (in eng), Indian Pediatr, vol. 50, no. 5, pp. 508-10, May 8 2013.
13. L. Gérinière, Y. Bastion, C. Dumontet, G. Salles, D. Espinouse, and B. Coiffier, "Heterogeneity of acute lymphoblastic leukemia in HIV-
seropositive patients," (in eng), Ann Oncol, vol. 5, no. 5, pp. 437-40, May 1994.
14. S. Sehgal, S. Mujtaba, D. Gupta, R. Aggarwal, and R. K. Marwaha, "High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: a preliminary study," (in eng), Indian J Pathol Microbiol, vol. 53, no. 1, pp. 63-7, Jan-Mar 2010.
15. L. G. Spector, et al, "Epidemiology and etiology. In Childhood Leukemias," England: Cambridge University Press, 2006.
16. T. Chowdhury and H. J. Brady, "Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia," (in eng), Blood Cells Mol Dis, vol. 40, no. 2, pp. 192-9, Mar-Apr 2008.
80 17. L. Seewald, J. W. Taub, K. W. Maloney, and E. R. McCabe, "Acute
leukemias in children with Down syndrome," (in eng), Mol Genet Metab,
vol. 107, no. 1-2, pp. 25-30, Sep 2012.
18. J. C. Alvarnas et al., "Acute Lymphoblastic Leukemia, Version 2.2015," (in eng), J Natl Compr Canc Netw, vol. 13, no. 10, pp. 1240-79, Oct 2015. 19. E. J. Jabbour, S. Faderl, and H. M. Kantarjian, "Adult acute lymphoblastic
leukemia," (in eng), Mayo Clin Proc, vol. 80, no. 11, pp. 1517-27, Nov 2005.
20. "National Institute of Hematology and Blood Transfusion. V. Lơ xê mi cấp. Available from: https://www.nihbt.org.vn/huyet-hoc-lam-sang/lo-xe- mi-cap/p187i8521.html.," 2019.
21. D. A. Arber et al., "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia," (in eng), Blood,
vol. 127, no. 20, pp. 2391-405, May 19 2016.
22. J. M. Rowe et al., "Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993," (in eng), Blood, vol. 106, no. 12, pp. 3760-7, Dec 1 2005.
23. "American Cancer Society. Acute Lymphocytic Leukemia (ALL) Subtypes and Prognostic Factors. ," Available from:
https://www.cancer.org/cancer/acute-lymphocytic-leukemia/detection- diagnosis-staging/how-classified.html., 2019.
24. X. Thomas et al., "Outcome of treatment in adults with acute
lymphoblastic leukemia: analysis of the LALA-94 trial," (in eng), J Clin Oncol, vol. 22, no. 20, pp. 4075-86, Oct 15 2004.
25. H. Rafei, H. M. Kantarjian, and E. J. Jabbour, "Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia," (in eng), Br J
Haematol, vol. 188, no. 2, pp. 207-223, Jan 2020.
26. E. A. Raetz et al., "Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study," (in eng), J Clin Oncol, vol. 26, no. 22, pp. 3756-62, Aug 1 2008.
27. J. M. Redman, E. M. Hill, D. AlDeghaither, and L. M. Weiner,
"Mechanisms of action of therapeutic antibodies for cancer," (in eng), Mol Immunol, vol. 67, no. 2 Pt A, pp. 28-45, Oct 2015.
28. J. B. Kaplan, M. Grischenko, and F. J. Giles, "Blinatumomab for the treatment of acute lymphoblastic leukemia," (in eng), Invest New Drugs,
vol. 33, no. 6, pp. 1271-9, Dec 2015.
29. J. F. DiJoseph et al., "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B- lymphoid malignancies," (in eng), Blood, vol. 103, no. 5, pp. 1807-14, Mar 1 2004.
30. H. Dai, Y. Wang, X. Lu, and W. Han, "Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy," (in eng), Journal of the National Cancer Institute, vol. 108, no. 7, p. djv439, 2016.
31. Z. Zhao, Y. Chen, N. M. Francisco, Y. Zhang, and M. Wu, "The application of CAR-T cell therapy in hematological malignancies:
81 advantages and challenges," Acta Pharmaceutica Sinica B, vol. 8, no. 4, pp. 539-551, 2018/07/01/ 2018.
32. C. L. Lorentzen and P. T. Straten, "CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute
Lymphoblastic Leukaemia," (in eng), Scand J Immunol, vol. 82, no. 4, pp. 307-19, Oct 2015.
33. N. Singh, N. V. Frey, S. A. Grupp, and S. L. Maude, "CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia," (in eng), Curr Treat Options Oncol, vol. 17, no. 6, p. 28, Jun 2016.
34. G. Gross, T. Waks, and Z. Eshhar, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity," (in eng), Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 10024-10028, 1989. 35. F. Letourneur and R. D. Klausner, "T-cell and basophil activation through
the cytoplasmic tail of T-cell-receptor zeta family proteins," (in eng),
Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 20, pp. 8905-8909, 1991.
36. Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors," (in eng), Proc Natl Acad Sci U S A, vol. 90, no. 2, pp. 720-4, Jan 15 1993.
37. M. H. Kershaw et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer," (in eng), Clin Cancer Res, vol. 12, no. 20 Pt 1, pp. 6106-15, Oct 15 2006.
38. B. Savoldo et al., "CD28 costimulation improves expansion and
persistence of chimeric antigen receptor-modified T cells in lymphoma patients," (in eng), J Clin Invest, vol. 121, no. 5, pp. 1822-6, May 2011. 39. D. Hollyman et al., "Manufacturing validation of biologically functional T
cells targeted to CD19 antigen for autologous adoptive cell therapy," (in eng), J Immunother, vol. 32, no. 2, pp. 169-80, Feb-Mar 2009.
40. R. J. Brentjens et al., "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia," (in eng), Science translational medicine, vol. 5, no. 177, pp. 177ra38-177ra38, 2013.
41. S. Inman, "GSK drug combination approved for advanced melanoma," (in eng), Am J Manag Care, vol. 20, no. 2 Spec No., p. E10, Feb 2014.
42. A. Mullard, "FDA approves first CAR T therapy," (in eng), Nat Rev Drug Discov, vol. 16, no. 10, p. 669, Sep 29 2017.
43. C. Zhang, J. Liu, J. F. Zhong, and X. Zhang, "Engineering CAR-T cells,"
Biomarker Research, vol. 5, no. 1, p. 22, 2017/06/24 2017. 44. M. Pulé, et al., "CHIMERIC ANTIGEN RECEPTOR (CAR)
COMPRISING A CD19-BINDING DOMAIN," U.B. Plc, Editor. 2015: England, 2015.
45. A. Hombach, A. A. Hombach, and H. Abken, "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids
82 'off-target' activation and unintended initiation of an innate immune
response," (in eng), Gene Ther, vol. 17, no. 10, pp. 1206-13, Oct 2010. 46. D. Abate-Daga and M. L. Davila, "CAR models: next-generation CAR
modifications for enhanced T-cell function," (in eng), Molecular therapy oncolytics, vol. 3, pp. 16014-16014, 2016.
47. H. Zhang et al., "4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy," (in eng), J Immunol, vol. 179, no. 7, pp. 4910-8, Oct 1 2007.
48. S. K. Tasian and R. A. Gardner, "CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)," (in eng), Ther Adv Hematol, vol. 6, no. 5, pp. 228-41, Oct 2015.
49. A. J. Smith, J. Oertle, D. Warren, and D. Prato, "Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective," Journal of Cellular Immunotherapy, vol. 2, no. 2, pp. 59-68, 2016/11/01/ 2016.
50. T. Brocker, "Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells," (in eng),
Blood, vol. 96, no. 5, pp. 1999-2001, Sep 1 2000.
51. M. Croft, "Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?," (in eng), Nat Rev Immunol, vol. 3, no. 8, pp. 609-20, Aug 2003.
52. H. M. Finney, A. N. Akbar, and A. D. Lawson, "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain," (in eng), J Immunol, vol. 172, no. 1, pp. 104-13, Jan 1 2004.
53. B. Cai et al., "Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in
refractory acute lymphoblastic leukemia," (in eng), Journal of hematology & oncology, vol. 9, no. 1, pp. 131-131, 2016.
54. Y. Hu et al., "Predominant cerebral cytokine release syndrome in CD19- directed chimeric antigen receptor-modified T cell therapy," Journal of Hematology & Oncology, vol. 9, no. 1, p. 70, 2016/08/15 2016.
55. M. C. Milone et al., "Chimeric receptors containing CD137 signal
transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo," (in eng), Mol Ther, vol. 17, no. 8, pp. 1453-64, Aug 2009.
56. G. Enblad, H. Karlsson, and A. S. Loskog, "CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma," (in eng), Hum Gene Ther, vol. 26, no. 8, pp. 498-505, Aug 2015.
57. X.-Y. Tang et al., "Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute
lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol," BMJ Open, vol. 6, no. 12, p. e013904, 2016.
58. D. Gomes da Silva et al., "Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-
83 T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling," Blood, vol. 128, no. 22, p. 1851, 2016/01/01/ 2016. 59. M. Chmielewski, C. Kopecky, A. A. Hombach, and H. Abken, "IL-12
release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression," (in eng), Cancer Res,
vol. 71, no. 17, pp. 5697-706, Sep 1 2011.
60. S. P. Kerkar et al., "Tumor-specific CD8+ T cells expressing interleukin- 12 eradicate established cancers in lymphodepleted hosts," (in eng),
Cancer Res, vol. 70, no. 17, pp. 6725-34, Sep 1 2010.
61. M. Chmielewski and H. Abken, "TRUCKs: the fourth generation of
CARs," (in eng), Expert Opin Biol Ther, vol. 15, no. 8, pp. 1145-54, 2015. 62. J. Marks-Konczalik et al., "IL-2-induced activation-induced cell death is
inhibited in IL-15 transgenic mice," (in eng), Proc Natl Acad Sci U S A,
vol. 97, no. 21, pp. 11445-50, Oct 10 2000.
63. E. Lanitis et al., "Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression," (in eng), J Exp Med,
vol. 218, no. 2, Feb 1 2021.
64. L. V. Hurton et al., "Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells," (in eng),
Proc Natl Acad Sci U S A, vol. 113, no. 48, pp. E7788-e7797, Nov 29 2016.
65. J. Feng et al., "Treatment of Aggressive T Cell Lymphoblastic
Lymphoma/leukemia Using Anti-CD5 CAR T Cells," (in eng), Stem Cell Rev Rep, vol. 17, no. 2, pp. 652-661, Apr 2021.
66. B. L. Levine, "Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells," (in eng), Cancer Gene Ther, vol. 22, no. 2, pp. 79-84, Mar 2015.
67. X. Wang and I. Rivière, "Clinical manufacturing of CAR T cells:
foundation of a promising therapy," Molecular Therapy - Oncolytics, vol. 3, p. 16015, 2016/01/01/ 2016.
68. M. Kalos et al., "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia," (in eng), Sci Transl Med, vol. 3, no. 95, p. 95ra73, Aug 10 2011.
69. B. L. Levine, J. Miskin, K. Wonnacott, and C. Keir, "Global
Manufacturing of CAR T Cell Therapy," (in eng), Mol Ther Methods Clin Dev, vol. 4, pp. 92-101, Mar 17 2017.
70. N. J. Piscopo et al., "Bioengineering Solutions for Manufacturing Challenges in CAR T Cells," (in eng), Biotechnol J, vol. 13, no. 2, Feb 2018.
71. B. Tumaini et al., "Simplified process for the production of anti-CD19- CAR-engineered T cells," (in eng), Cytotherapy, vol. 15, no. 11, pp. 1406- 15, Nov 2013.
72. Z. Jin et al., "The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor," (in eng), Gene Ther, vol. 18, no. 9, pp. 849-56, Sep 2011.
84 73. P. V. Manuri et al., "piggyBac transposon/transposase system to generate
CD19-specific T cells for the treatment of B-lineage malignancies," (in eng), Hum Gene Ther, vol. 21, no. 4, pp. 427-37, Apr 2010.
74. A. M. Geurts et al., "Gene transfer into genomes of human cells by the sleeping beauty transposon system," (in eng), Mol Ther, vol. 8, no. 1, pp. 108-17, Jul 2003.
75. X. Huang et al., "Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells," (in eng), Mol Ther, vol. 18, no. 10, pp. 1803-13, Oct 2010.
76. L. Mátés et al., "Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates," (in eng), Nat Genet, vol. 41, no. 6, pp. 753-61, Jun 2009.
77. R. Monjezi et al., "Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors," (in eng),
Leukemia, vol. 31, no. 1, pp. 186-194, Jan 2017.
78. H. Singh et al., "Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells," (in eng), PLoS One, vol. 8, no. 5, p. e64138, 2013.
79. P. Vormittag, R. Gunn, S. Ghorashian, and F. S. Veraitch, "A guide to manufacturing CAR T cell therapies," (in eng), Curr Opin Biotechnol, vol. 53, pp. 164-181, Oct 2018.
80. F. L. Locke et al., "Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma," (in eng), Mol Ther, vol. 25, no. 1, pp. 285-295, Jan 4 2017. 81. M. Poorebrahim et al., "Production of CAR T-cells by GMP-grade
lentiviral vectors: latest advances and future prospects," (in eng), Crit Rev Clin Lab Sci, vol. 56, no. 6, pp. 393-419, Sep 2019.
82. S. L. Maude et al., "Chimeric antigen receptor T cells for sustained remissions in leukemia," (in eng), N Engl J Med, vol. 371, no. 16, pp. 1507-17, Oct 16 2014.
83. "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia," (in eng), N Engl J Med, vol. 374, no. 10, p. 998, Mar 10 2016.
84. T. Gargett, N. Truong, L. M. Ebert, W. Yu, and M. P. Brown,
"Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype," (in eng),
Cytotherapy, vol. 21, no. 6, pp. 593-602, Jun 2019.